References
Baker KM, Chemin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure overload cardiac hypertrophy in rats. American Journal of Physiology 259: H324–H332, 1990.
Bussmann WD, Goerke S, Schneider W, Kaltenbach M. Angiotensin-Converting-Enzym-Hemmer bei Angina Pectoris. Deutsche Medizinische Wochenschrift 113: 548–550, 1988.
Cleland JGF, Henderson E, McLenachan J, Findlay J, Dargie HJ. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. Journal of the American College of Cardiology 17: 733–739, 1991.
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. New England Journal of Medicine 314: 1547–1552, 1986.
Cohn JK. Johnson G, Ziesche S, Cobb F, Francis G, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine 325: 303–310, 1991.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine 316: 1429–1435, 1987.
Cushman D, Cheung H, Sabo E, Ondetti M. Design of potent competitive inhibitors of angiotensin-converting enzyme car-boxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16: 5484–5491, 1977.
Dakak N, Makhoul N, Flugelman MY, Merdier A, Shehadeh H, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. American Journal of Cardiology 66: 608–613, 1990.
Daly P, Mettauer B, Rauleau J-L, Cousineau D, Burgess JH. Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. Circulation 71: 317–325, 1985.
Dzau VJ, Colucci WS, Hollenberg NK, William GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63: 645–651, 1981.
Ertl G. Angiotensin converting enzyme inhibitors and ischaemic heart disease. European Heart Journal 9: 716–727, 1988.
Ertl G, Gaudron P, Hu K. Ventricular remodeling after myocardial infarction. Experimental and clinical studies. Basic Research in Cardiology 88 (Suppl.): 125–136, 1993.
Ertl G, Kloner RA, Alexander R, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 65: 40–48, 1982.
Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling following myocardial infarction: potential mechanisms and early predictors. Circulation 87: 755–763, 1993.
Gaudron P, Eilles C, Ertl G, Kochsiek K. Compensatory and noncompensatory left ventricular dilatation after myocardial infarction: time course and hemodynamic consequenes at rest and during exercise. American Heart Journal 123: 377–385, 1992.
Gibbons GH, Dzau VJ. Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension. Cardiovascular Drugs and Therapy 4: 237–242, 1990.
Gibbs JSR, Crean PA, Mockus L, Wright C, Sutton GC, et al. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. British Heart Journal 62: 112–117, 1989.
Goldblatt H, Lynch J, Hanzal R, Ranar F, Sumerville W. Studies on experimental hypertension. I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. Journal of Experimental Medicine 59: 347–379, 1934.
Herrman J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the holy grail? (Part I). Drugs 46: 18–52, 1993.
Hirooka Y, Imaizumi T, Masaki H, Ando S-I, Harada S, et al. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 20: 175–180, 1992.
Ikram H, Low CJS, Shirlaw T, Webb CM, Richards AM, et al. Antianginal, hemodynamic and coronary vascular effects of captopril in stable angina pectoris. American Journal of Cardiology 66: 164–167, 1990.
Katz RJ, Levy WS, Buff L, Wassermann AG. Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation 83: 1271–1277, 1991.
Keck M. Der Einfluss von Captopril auf Ischämieparameter bei stabiler Belastungskoronarinsuffizienz. Herz/Kreislauf 19: 319–321, 1987.
Klein WW, Khurmi NS, Eber B, Dusleag J. Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina. Journal of the American College of Cardiology 16: 948–956, 1990.
Lai C, Onnis E, Orani E, Pirisi R, Soro A, et al. Effects of enalapril in normotensive patients with stable effects angina: a double blind, placebo controlled study. Drugs Under Experimental Clinical Research 16: 299–305, 1990.
Lam JYT, Lacoste L, Bourassa MG. Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries. Circulation 85: 1542–1547, 1992.
Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circulation Research 68: 905–921, 1991.
Metelitsa VI, Mansevich SY, Kozyreva MP, Slastnikova ID. Enhancement of the efficacy of isosorbide dinitrate by captopril in stable angina pectoris. American Journal of Cardiol 69: 291–296, 1992.
Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural and endocrine dependence. Circulation 83: 13–25, 1991.
Moye LA, Pfeffer MA, Braunwald E. For the SAVE Investigators: Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. American Journal of Cardiology 68: 70D–79D, 1991.
Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the Mercator study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 86: 100–110, 1992.
Patchett A, Harris E, Tristram E. A new class of angiotensin-converting enzyme inhibitors. Nature 288: 280–283, 1980.
Perondi R, Saino A, Tio RA, Pomidossi G, Gregorini L, et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 85: 2004–2013, 1992.
Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161–1172, 1990.
Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown E, et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. New England Journal of Medicine 327: 669–677, 1992.
Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. New England Journal of Medicine 319: 80–86, 1988.
Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circulation Research 57: 84–95, 1985a.
Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of longterm therapy with captopril. Circulation 72: 406–412, 1985b.
Powell JS, Muller RKM, Rouge M, Kuhn H, Hefti F, et al. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. Journal of Cardiovascular Pharmacology 16: S42–S49, 1990.
Rietbrock N, Thurmann P, Kirsten R, Schneider W. Antiischämische Wirksamkeit von Enalapril bei koronarer Herzkrankheit. Deutsche Medizinische Wochenschrift 114: 300–302, 1988.
Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet I: 255–259, 1988.
Sogaard P, Gotzsche C-O, Ravkilde J, Thygesen K. Effects of captopril on ischaemia and dysfunction of the left ventricle after myocardial infarction. Circulation 87: 1093–1099, 1993.
SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine 327: 685–691, 1992.
Strozzi C, Cocco G, Portaluppi F, Padula A, Urso L, et al. Ergometric evaluation of the effects of captopril in hypertensive patients with stable angina. Journal of Hypertension 3: S147–S148, 1985.
Strozzi C, Portaluppi F, Cocco G, Urso L. Ergometric evaluation of the effects of enalapril maleate in normotensive patients with stable angina. Clinical Cardiology 11: 246–249, 1988.
Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). New England Journal of Medicine 327: 678–684, 1992.
Tigerstedt R, Bergmann PG. Niere und Kreislauf. Scandinavian Archives of Physiology 8: 223–271, 1898.
Tzivoni D, Gottlieb S, Khurmi N, Medina A, Gavish A, et al. Effect of benazepril on myocardial ischaemia in patients with chronic stable angina pectoris. European Heart Journal 13: 1129–1134, 1992.
Unterberg C, Buchwald A, Vogt A, Wiegand W. Akute Effekte des Angiotensin-Converting-Enzym-Hemmers Ramipril bei Patienten mit koronarer Herzerkrankung. Medizinische Klinik 85: 78–81, 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ertl, G. Angiotensin Converting Enzyme Inhibitors in Angina and Myocardial Infarction. Drugs 46, 209–218 (1993). https://doi.org/10.2165/00003495-199346020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199346020-00001